Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

My name is John, and I’ll be your conference operator today ... the impact of cost reduction initiatives on cash burn and runway, the ability to compete with GLP-1 drugs or use of the Allurion Program ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Just sev­en months af­ter un­veil­ing with $290 mil­lion, obe­si­ty biotech Met­sera is back with an­oth­er $215 mil­lion.

On just the Hims & Hers platform alone, nearly 80,000 individuals have shared they cannot access branded GLP-1 medications. Those numbers are particularly ... cannot access their medications, with ...

Whether these departments get the money will be decided later, but the Scene listened in on requests from the Department of ...

Short-acting RA: Provides shorter GLP-1 receptor activation. The effects last only for a few hours. Examples include ...

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...

GLP-1s seem to be everywhere. The appetite suppressant drugs, with brand names like Ozempic and Wegovy, have grown in ...